Table 3.

Characteristics of LACE cohort by hours/week of moderate intensity physical activity

Hours per week of moderate activity
P*
<1 h (n = 490)1-<3 h (n = 502)3-<6 h (n = 523)≥6 h (n = 433)
Age at enrollment, mean y (SD)62.8 (11.1)60.0 (11.2)59.9 (10.3)59.6 (10.2)<0.0001
Race, n (%)0.15
    White383 (78.2)409 (81.5)432 (82.6)362 (83.6)
    Other107 (21.8)93 (18.5)91 (17.4)71 (16.4)
Education, n (%)0.0001
    High school graduate or less167 (34.1)125 (24.9)116 (22.2)116 (26.9)
    Some college178 (36.3)201 (40.0)198 (37.9)143 (33.2)
    College graduate or more145 (29.6)176 (35.1)209 (40.0)172 (39.9)
Smoking status, n (%)0.40
    Never263 (53.8)279 (55.8)269 (51.6)234 (54.3)
    Past184 (37.6)187 (37.4)222 (42.6)165 (38.3)
    Current42 (8.6)34 (6.8)30 (5.8)32 (7.4)
BMI at enrollment, mean kg/m2 (SD)28.9 (6.3)27.9 (5.8)26.9 (5.6)26.2 (5.1)<0.0001
Weight at 18 y, mean lbs (SD)120.5 (17.6)120.4 (16.2)122.5 (17.3)120.6 (16.9)0.16
Menopausal status, n (%)0.03
    Postmenopausal340 (69.4)315 (62.8)333 (63.5)286 (65.9)
    Premenopausal95 (19.4)117 (23.3)100 (19.1)97 (22.4)
    Undetermined55 (11.2)70 (13.9)91 (17.4)51 (11.7)
Family history of breast cancer, n (%)0.74
    No389 (79.4)408 (81.3)411 (78.6)343 (79.2)
    Yes101 (20.6)94 (18.7)112 (21.4)90 (20.8)
Stage, n (%)0.21
    I218 (44.7)233 (46.5)257 (49.1)219 (50.6)
    IIa163 (33.4)180 (35.9)160 (30.5)147 (34.0)
    IIb94 (19.3)72 (14.4)90 (17.2)56 (12.9)
    IIIa13 (2.7)16 (3.2)17 (3.2)11 (2.5)
Type of surgery, n (%)0.60
    Conserving244 (49.8)265 (52.8)255 (48.7)218 (50.3)
    Mastectomy246 (50.2)237 (47.2)269 (51.3)215 (49.7)
Chemotherapy, n (%)0.03
    No232 (48.2)195 (39.0)230 (44.3)188 (43.5)
    Yes249 (51.8)305 (61.0)289 (55.7)244 (56.5)
Radiation therapy, n (%)0.83
    No179 (38.2)176 (35.6)197 (37.9)155 (36.8)
    Yes290 (61.8)319 (64.4)323 (62.1)266 (63.2)
Number of positive nodes, n (%)0.06
    Node negative282 (60.6)291 (62.1)319 (65.8)283 (68.9)
    1-3125 (26.9)121 (25.8)121 (24.9)99 (24.1)
    ≥358 (12.5)57 (12.1)45 (9.3)29 (7.1)
Tamoxifen use, n (%).69
    No116 (23.7)121 (24.1)113 (21.6)94 (21.7)
    Yes374 (76.3)381 (75.9)411 (78.4)340 (78.3)
ER/PR receptor status, n (%)0.33
    ER+, PR+330 (68.6)319 (64.4)366 (70.8)296 (69.0)
    ER+, PR-62 (12.9)73 (14.8)71 (13.7)67 (15.6)
    ER-, PR+6 (1.2)12 (2.4)9 (1.7)7 (1.6)
    ER-, PR-83 (17.3)91 (18.4)71 (13.7)59 (13.8)
Time from diagnosis to enrollment, mean y (SD)1.9 (0.5)1.9 (0.6)1.9 (0.6)1.9 (0.6)0.91
Follow-up time, mean y (SD)
    To recurrence7.0 (1.6)7.2 (1.6)7.2 (1.5)7.2 (1.5)0.08
    To death7.2 (1.3)7.4 (1.3)7.4 (1.2)7.4 (1.3)0.08
  • * ANOVA to test for differences in means of continuous variables; chi-square tests to evaluate differences in proportions for categorical variables.